Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Alpha Cognition Inc ACOGF


Primary Symbol: C.ACOG

Healthcare Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


CSE:ACOG - Post by User

Alpha Cognition Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(83)
•••
Post by biggonadson Feb 28, 2022 1:49pm
87 Views
Post# 34468395

Positive data from Alpha-1062 TBI program

Positive data from Alpha-1062 TBI programAlpha Cognition announced histology data from their intranasal Alpha-1062 traumatic brain injury (TBI) program. Essentially the results presented demonstrate that Alpha-1062 exhibits both neuroprotection and enhances restoration of sensory, motor and cognitive performance in this model of moderate traumatic brain injury.The histological results, in addition to positive functional data previously released, strongly support the further development of Alpha-1062 for TBI treatments. FYI - Alpha 0602, has been granted orphan drug designation which enables ACOG a 7-year marketing exclusivity and prohibits FDA approvals for similar drugs during this period. https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/alpha-cognition-announces-positive-neuroprotection-data-from-pre-clinical-study-of-alpha-1062-for-traumatic-brain-injury
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities